Proposed Collection; 60-Day Comment Request; Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 72004-72005 [2014-28498]

Download as PDF 72004 Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices related questions with inquiries into the communication channels through which understanding is being obtained, and assessment of FDA-regulated material. This survey will extend the information collected and priorities from HINTS which have been to provide a comprehensive assessment of the American public’s current access to, and use of, information about cancer across the cancer care continuum from cancer prevention, early detection, diagnosis, treatment, and survivorship. OMB approval is requested for 1 year. There are no costs to respondents other than their time. The total estimated annualized burden hours are 2,159. ESTIMATED ANNUALIZED BURDEN HOURS Type of respondents Number of respondents Number of responses per respondent Average burden per response (in hours) Total annual burden hour Individuals ........................................................................................................ 4,318 1 30/60 2,159 Dated: November 24, 2014. Karla Bailey, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 2014–28513 Filed 12–3–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI) In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:23 Dec 03, 2014 Jkt 235001 the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To Submit Comments and For Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Anthony Dickherber, NCI Center for Strategic Scientific Initiatives, 31 Center Drive, Rm10A33, Bethesda, MD 20892 or call non-toll-free number 301–547–9980 or Email your request, including your address to: dickherberaj@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Surveys and Interviews to Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 0925–NEW, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: The purpose of the proposed evaluation is to pursue a comprehensive process and outcome assessment of the 15-year old Innovative Molecular Analysis Technologies (IMAT) program. While the program consistently offers promising indicators of success, the full program has not been evaluated since 2008, and never in as comprehensive a manner as has been formulated in the current evaluation plan. An outcome evaluation of the long-standing National Cancer Institute’s (NCI) IMAT program presents a rich and unique opportunity likely to serve institutes across the PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 National Institutes of Health (NIH), and perhaps other federal agencies, considering the costs and benefits of directing resources towards supporting technology development. An award through the NIH Evaluation Set-Aside program to support this evaluation, for which NIH-wide relevance is a principle element of determining merit for support, is testament to this. The evaluation serves as an opportunity to gauge the impact of investments in technology development and also to assess the strengths and weaknesses of phased innovation award mechanisms. Like all institutes and centers (ICs) of the NIH, NCI seeks opportunities for improving their programs’ utility for the broad continuum of researchers, clinicians and ultimately patients. NCI Director Harold Varmus and other leadership across NCI, as well as the NCI Board of Scientific Advisors, will be the primary users of the evaluation results. Findings are primarily intended for considering the long-term strategy to support innovative technology development and how to more efficiently translate emerging capabilities through such technologies into the promised benefits for cancer research and clinical care. Interviews with grantees, program officers, review officers, and other NIH awardees make up a crucial component of the evaluation plan and will largely follow set survey protocols. Specific near-term aims include the use of this information to consider the utility of continued investment through existing solicitations and in strategic planning generally for institute support for innovative technology development. OMB approval is requested for 1 year. There are no costs to respondents other than their time. The total estimated annualized burden hours are 575. E:\FR\FM\04DEN1.SGM 04DEN1 72005 Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Form name Type of respondents IMAT Awardee Interview ................... Evaluation Web-based Survey .......... IMAT Awardees ............................... IMAT Awardees, and other NIH Awardees (Comparison group). Technology End-Users .................... Tech End Users Interview ................. Dated: November 24, 2014. Karla Bailey, NCI Project Clearance Liaison, National Institutes of Health. 1 30/60 100 450 50 1 30/60 25 FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7– 1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services Administration, HHS. AGENCY: ACTION: Notice. The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHScertified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:23 Dec 03, 2014 Jkt 235001 The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies. To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHScertified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens: SUPPLEMENTARY INFORMATION: Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies HHS-Certified Instrumented Initial Testing Facilities Gamma-Dynacare Medical Laboratories, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780–784–1190 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 Total annual burden hours 1 1 BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Average burden per response (in hours) 100 900 at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://beta.samhsa.gov/ workplace. [FR Doc. 2014–28498 Filed 12–3–14; 8:45 am] Number of responses per respondent HHS-Certified Laboratories ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264 Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615– 255–2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories) Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/ 800–433–3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.) Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.) Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917 DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800– 235–4890 ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662– 236–2609 Fortes Laboratories, Inc., 25749 SW., Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023 Gamma-Dynacare Medical Laboratories *, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630 Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986, (Formerly: Roche Biomedical Laboratories, Inc.) Laboratory Corporation of America Holdings, 1904 Alexander Drive, E:\FR\FM\04DEN1.SGM 04DEN1

Agencies

[Federal Register Volume 79, Number 233 (Thursday, December 4, 2014)]
[Notices]
[Pages 72004-72005]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28498]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Proposed Collection; 60-Day Comment Request; Surveys and 
Interviews To Support an Evaluation of the Innovative Molecular 
Analysis Technologies (IMAT) Program (NCI)

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of 
the Paperwork Reduction Act of 1995, for opportunity for public comment 
on proposed data collection projects, the National Cancer Institute 
(NCI), National Institutes of Health (NIH), will publish periodic 
summaries of proposed projects to be submitted to the Office of 
Management and Budget (OMB) for review and approval.
    Written comments and/or suggestions from the public and affected 
agencies are invited on one or more of the following points: (1) 
Whether the proposed collection of information is necessary for the 
proper performance of the function of the agency, including whether the 
information will have practical utility; (2) The accuracy of the 
agency's estimate of the burden of the proposed collection of 
information, including the validity of the methodology and assumptions 
used; (3) Ways to enhance the quality, utility, and clarity of the 
information to be collected; and (4) Ways to minimize the burden of the 
collection of information on those who are to respond, including the 
use of appropriate automated, electronic, mechanical, or other 
technological collection techniques or other forms of information 
technology.
    To Submit Comments and For Further Information: To obtain a copy of 
the data collection plans and instruments, submit comments in writing, 
or request more information on the proposed project, contact: Anthony 
Dickherber, NCI Center for Strategic Scientific Initiatives, 31 Center 
Drive, Rm10A33, Bethesda, MD 20892 or call non-toll-free number 301-
547-9980 or Email your request, including your address to: 
dickherberaj@mail.nih.gov. Formal requests for additional plans and 
instruments must be requested in writing.
    Comment Due Date: Comments regarding this information collection 
are best assured of having their full effect if received within 60 days 
of the date of this publication.
    Proposed Collection: Surveys and Interviews to Support an 
Evaluation of the Innovative Molecular Analysis Technologies (IMAT) 
Program (NCI), 0925-NEW, National Cancer Institute (NCI), National 
Institutes of Health (NIH).
    Need and Use of Information Collection: The purpose of the proposed 
evaluation is to pursue a comprehensive process and outcome assessment 
of the 15-year old Innovative Molecular Analysis Technologies (IMAT) 
program. While the program consistently offers promising indicators of 
success, the full program has not been evaluated since 2008, and never 
in as comprehensive a manner as has been formulated in the current 
evaluation plan. An outcome evaluation of the long-standing National 
Cancer Institute's (NCI) IMAT program presents a rich and unique 
opportunity likely to serve institutes across the National Institutes 
of Health (NIH), and perhaps other federal agencies, considering the 
costs and benefits of directing resources towards supporting technology 
development. An award through the NIH Evaluation Set-Aside program to 
support this evaluation, for which NIH-wide relevance is a principle 
element of determining merit for support, is testament to this. The 
evaluation serves as an opportunity to gauge the impact of investments 
in technology development and also to assess the strengths and 
weaknesses of phased innovation award mechanisms.
    Like all institutes and centers (ICs) of the NIH, NCI seeks 
opportunities for improving their programs' utility for the broad 
continuum of researchers, clinicians and ultimately patients. NCI 
Director Harold Varmus and other leadership across NCI, as well as the 
NCI Board of Scientific Advisors, will be the primary users of the 
evaluation results. Findings are primarily intended for considering the 
long-term strategy to support innovative technology development and how 
to more efficiently translate emerging capabilities through such 
technologies into the promised benefits for cancer research and 
clinical care. Interviews with grantees, program officers, review 
officers, and other NIH awardees make up a crucial component of the 
evaluation plan and will largely follow set survey protocols. Specific 
near-term aims include the use of this information to consider the 
utility of continued investment through existing solicitations and in 
strategic planning generally for institute support for innovative 
technology development.
    OMB approval is requested for 1 year. There are no costs to 
respondents other than their time. The total estimated annualized 
burden hours are 575.

[[Page 72005]]



                                                            Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                              Average
                                                                                             Number of       Number of      burden per     Total annual
                   Form name                               Type of respondents              respondents    responses per   response  (in   burden hours
                                                                                                            respondent        hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
IMAT Awardee Interview.........................  IMAT Awardees..........................             100               1               1             100
Evaluation Web-based Survey....................  IMAT Awardees, and other NIH Awardees               900               1           30/60             450
                                                  (Comparison group).
Tech End Users Interview.......................  Technology End-Users...................              50               1           30/60              25
--------------------------------------------------------------------------------------------------------------------------------------------------------


    Dated: November 24, 2014.
Karla Bailey,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2014-28498 Filed 12-3-14; 8:45 am]
BILLING CODE 4140-01-P